BRPI9915552B8 - pirimidinas inibidoras da reprodução do hiv - Google Patents

pirimidinas inibidoras da reprodução do hiv

Info

Publication number
BRPI9915552B8
BRPI9915552B8 BRPI9915552A BR9915552A BRPI9915552B8 BR PI9915552 B8 BRPI9915552 B8 BR PI9915552B8 BR PI9915552 A BRPI9915552 A BR PI9915552A BR 9915552 A BR9915552 A BR 9915552A BR PI9915552 B8 BRPI9915552 B8 BR PI9915552B8
Authority
BR
Brazil
Prior art keywords
alkyl
optionally substituted
nhc
amino
alkyloxycarbonyl
Prior art date
Application number
BRPI9915552A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9915552B1 (pt
BR9915552A (pt
Inventor
De Corte Bart
Yung Ho Chih
William Ludovici Donald
Heeres Jan
Jeanne Alfons Vans Aken Koen
Jozef Lodenwijk Marcel Andries Koenraad
Maria Henricus Koymans Lucien
Rene De Jonge Marc
Joseph Kukla Michael
Adriaan Jan Janssen Paul
W Kavash Robert
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26805159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9915552(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR9915552A publication Critical patent/BR9915552A/pt
Publication of BR9915552B1 publication Critical patent/BR9915552B1/pt
Publication of BRPI9915552B8 publication Critical patent/BRPI9915552B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI9915552A 1998-11-10 1999-09-24 pirimidinas inibidoras da reprodução do hiv BRPI9915552B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10779298P 1998-11-10 1998-11-10
US14396299P 1999-07-15 1999-07-15
PCT/EP1999/007417 WO2000027825A1 (en) 1998-11-10 1999-09-24 Hiv replication inhibiting pyrimidines

Publications (3)

Publication Number Publication Date
BR9915552A BR9915552A (pt) 2001-08-14
BR9915552B1 BR9915552B1 (pt) 2013-11-19
BRPI9915552B8 true BRPI9915552B8 (pt) 2021-05-25

Family

ID=26805159

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9915552A BRPI9915552B8 (pt) 1998-11-10 1999-09-24 pirimidinas inibidoras da reprodução do hiv

Country Status (41)

Country Link
US (5) US6878717B2 (enExample)
EP (2) EP1270560B1 (enExample)
JP (1) JP3635238B2 (enExample)
KR (1) KR100658489B1 (enExample)
CN (1) CN1214013C (enExample)
AP (1) AP1683A (enExample)
AR (1) AR024227A1 (enExample)
AT (2) ATE233740T1 (enExample)
AU (2) AU762523C (enExample)
BG (1) BG65103B1 (enExample)
BR (1) BRPI9915552B8 (enExample)
CA (1) CA2350801C (enExample)
CY (1) CY2008021I1 (enExample)
CZ (1) CZ301367B6 (enExample)
DE (3) DE122009000003I1 (enExample)
DK (1) DK1002795T3 (enExample)
EA (1) EA004049B1 (enExample)
EE (1) EE05086B1 (enExample)
ES (2) ES2338760T3 (enExample)
FR (1) FR09C0004I2 (enExample)
HK (1) HK1048817B (enExample)
HR (2) HRP20080359B1 (enExample)
HU (2) HU230394B1 (enExample)
ID (1) ID28376A (enExample)
IL (2) IL143023A0 (enExample)
LT (1) LTC1002795I2 (enExample)
LU (1) LU91528I2 (enExample)
MY (1) MY121108A (enExample)
NL (1) NL300373I2 (enExample)
NO (3) NO318801B1 (enExample)
NZ (1) NZ511116A (enExample)
OA (1) OA11674A (enExample)
PL (1) PL204427B1 (enExample)
PT (1) PT1002795E (enExample)
SI (1) SI1002795T1 (enExample)
SK (2) SK287270B6 (enExample)
TR (1) TR200101306T2 (enExample)
TW (1) TWI238161B (enExample)
UA (1) UA70966C2 (enExample)
WO (1) WO2000027825A1 (enExample)
ZA (1) ZA200103769B (enExample)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20080359B1 (hr) * 1998-11-10 2016-01-01 Janssen Pharmaceutica N.V. PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
AU775360B2 (en) * 1999-09-24 2004-07-29 Janssen Pharmaceutica N.V. Antiviral compositions
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
WO2001060816A1 (en) 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
CA2406562C (en) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
WO2001085699A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Prodrugs of hiv replication inhibiting pyrimidines
CA2429364C (en) * 2000-11-01 2007-01-02 Snapnames.Com, Inc. Domain name acquisition and management system and method
CA2449118A1 (en) 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
EP2090571B1 (de) * 2001-10-17 2012-05-16 Boehringer Ingelheim Pharma GmbH & Co. KG Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung
US7183288B2 (en) 2001-11-01 2007-02-27 Herwig Josephus Margareta Janssen, legal representative Amide derivatives as glycogen synthase kinase 3-β inhibitors
NZ531853A (en) 2001-11-01 2006-02-24 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2003076400A1 (en) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
KR20040094672A (ko) 2002-03-13 2004-11-10 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US20060034797A1 (en) * 2002-05-03 2006-02-16 Arien Albertina M E Polymeric micromulsions
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
AR040456A1 (es) 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
NZ538611A (en) * 2002-08-09 2007-03-30 Janssen Pharmaceutica Nv Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
HUE038446T2 (hu) 2002-09-20 2018-10-29 Alpharma Pharmaceuticals Llc Szekvesztráló alegység és releváns kompozíciók és módszerek
CN1717396A (zh) * 2002-11-28 2006-01-04 舍林股份公司 Chk-、Pdk-和Akt-抑制嘧啶,其制备及作为药物的用途
BRPI0406761A (pt) 2003-01-14 2005-12-20 Arena Pharm Inc Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
WO2004074266A1 (en) * 2003-02-07 2004-09-02 Janssen Pharmaceutica N.V. Hiv inhibiting 1,2,4-triazines
CA2513527C (en) 2003-02-07 2012-08-14 Janssen Pharmaceutica N.V. Pyrimidine derivatives for the prevention of hiv infection
ATE433447T1 (de) * 2003-02-20 2009-06-15 Smithkline Beecham Corp Pyrimiidinverbindungen
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005011702A1 (en) * 2003-07-17 2005-02-10 Tibotec Pharmaceuticals Ltd. Process for preparing particles containing an antiviral
US8178671B2 (en) 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
DE602004031641D1 (de) * 2003-09-25 2011-04-14 Janssen Pharmaceutica Nv Die replikation von hiv hemmende purinderivate
WO2005086061A2 (en) 2004-03-02 2005-09-15 Virco Bvba Estimation of clinical cut-offs
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US8193205B2 (en) 2004-07-28 2012-06-05 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
CA2575002C (en) 2004-08-10 2015-01-20 Janssen Pharmaceutica N.V. Hiv inhibiting 1,2,4-triazin-6-one derivatives
ES2380631T3 (es) * 2004-09-30 2012-05-17 Tibotec Pharmaceuticals Pirimidinas sustituidas en posición 5 inhibidoras de VIH
JP5008567B2 (ja) * 2004-09-30 2012-08-22 テイボテク・フアーマシユーチカルズ Hiv阻害性5−ヘテロシクリルピリミジン
CA2573976C (en) 2004-09-30 2014-04-29 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
WO2006045828A1 (en) 2004-10-29 2006-05-04 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
CA2583187A1 (en) * 2004-11-08 2006-05-18 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and etravirine
EP1814878B1 (en) 2004-11-24 2012-01-04 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
EP1856135B1 (en) 2005-01-19 2009-12-09 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
CA2599228C (en) * 2005-01-27 2014-05-13 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 2-( 4-cyanophenylamino) pyrimidine derivatives
WO2006087530A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
EP1853567B1 (en) * 2005-02-18 2014-12-31 Janssen R&D Ireland Hiv inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
JP5118978B2 (ja) * 2005-03-04 2013-01-16 テイボテク・フアーマシユーチカルズ Hiv阻害2−(4−シアノフェニル)−6−ヒドロキシルアミノピリミジン
EP1899323A2 (en) 2005-05-16 2008-03-19 AstraZeneca AB Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
IN2014DN04588A (enExample) 2005-05-26 2015-07-10 Tibotec Pharm Ltd
CN105348203B (zh) 2005-06-08 2018-09-18 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CN101355939A (zh) * 2005-10-06 2009-01-28 马萨诸塞大学 用于抑制hiv复制的新物质的组合物和合成
EP2388259A1 (en) 2005-10-28 2011-11-23 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
ES2396986T3 (es) 2006-01-19 2013-03-01 Janssen Pharmaceutica N.V. Derivados de piridina y pirimidina como inhibidores de histona desacetilasa
CA2635015C (en) 2006-01-19 2014-06-03 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
PT1981874E (pt) 2006-01-19 2009-09-02 Janssen Pharmactuica N V Derivados de aminofenil como novos inibidores de histonadesacetilase
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
AU2007233737B2 (en) 2006-03-30 2012-11-29 Janssen Sciences Ireland Uc HIV inhibiting 5-amido substituted pyrimidines
SI2004641T1 (sl) 2006-03-30 2011-02-28 Tibotec Pharm Ltd HIV inhibirajoči 5-(hidroksimetilen in aminometilen) substituirani pirimidini
PE20120006A1 (es) 2006-05-15 2012-02-02 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
ME01305B (me) 2006-06-06 2012-04-30 Tibotec Pharm Ltd Proces za pripremanje raspršivanjem osušenih formulacija tmc125
EP2484346B1 (en) 2006-06-19 2017-02-22 Alpharma Pharmaceuticals LLC Pharmaceutical compositions
JP2010506833A (ja) * 2006-10-11 2010-03-04 アルファーマ,インコーポレイテッド 医薬組成物
US20100041687A1 (en) 2006-12-06 2010-02-18 Thone Daniel Joseph Christiaan Hydrobromide salt of an anti-hiv compound
JP5283633B2 (ja) 2006-12-29 2013-09-04 テイボテク・フアーマシユーチカルズ Hiv阻害性5,6−置換ピリミジン
MX2009007005A (es) * 2006-12-29 2009-07-09 Tibotec Pharm Ltd Pirimidinas 6-sustituidas que inhiben el virus de inmunodeficiencia humana.
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
EP2212298B1 (en) * 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CN102105150B (zh) 2008-05-21 2014-03-12 阿里亚德医药股份有限公司 用作激酶抑制剂的磷衍生物
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
NZ624345A (en) 2008-06-27 2016-07-29 Celgene Avilomics Res Inc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TW201016676A (en) * 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
JP5748737B2 (ja) 2009-03-30 2015-07-15 ヤンセン・アールアンドデイ・アイルランド エトラビリンとニコチンアミドの共結晶
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
WO2010131118A2 (en) * 2009-05-12 2010-11-18 Pliva Hrvatska D.O.O. Polymorphs of etravirine and processes for preparation thereof
AP2858A (en) 2009-06-22 2014-02-28 Emcure Pharmaceuticals Ltd Process for synthesis of a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
MX2012014158A (es) 2010-06-04 2013-02-07 Hoffmann La Roche Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2).
CA2803848A1 (en) 2010-06-28 2012-01-05 Hetero Research Foundation A process for etravirine intermediate and polymorphs of etravirine
EP3144298A1 (en) 2010-08-10 2017-03-22 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2635284B1 (en) 2010-11-01 2019-12-18 Celgene CAR LLC Heterocyclic compounds and uses thereof
PH12013500880A1 (en) 2010-11-10 2013-07-01 Hoffmann La Roche Pyrazole aminopyrimidine derivatives as lrrk2 modulators
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
PL2702045T3 (pl) 2011-04-26 2018-04-30 Mylan Laboratories Ltd. Nowy sposób sporządzania Etrawiryny
KR101884010B1 (ko) 2011-05-04 2018-07-31 어리어드 파마슈티칼스, 인코포레이티드 Egfr-유도된 암의 세포 증식을 억제하는 화합물
WO2012170647A1 (en) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
ES2969977T3 (es) 2011-08-23 2024-05-23 Libertas Bio Inc Compuestos de pirimido-piridazinona y uso de los mismos
WO2013059572A1 (en) 2011-10-19 2013-04-25 Assia Chemical Industries Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
WO2013109354A2 (en) * 2011-12-07 2013-07-25 Texas Southern University Etravirine formulations and uses thereof
CN108658873B (zh) 2012-03-15 2021-09-14 西建卡尔有限责任公司 表皮生长因子受体激酶抑制剂的固体形式
SI2825042T1 (sl) 2012-03-15 2019-01-31 Celgene Car Llc Soli inhibitorja kinaze receptorja faktorja epidermalne rasti
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
US20150336900A1 (en) * 2012-10-29 2015-11-26 Biophore India Pharmaceuticals Pvt. Ltd. Process for the Synthesis of Etravirine and Its Intermediates
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA2894466A1 (en) 2012-12-21 2014-06-26 Patrick Colin Uses and methods for the treatment of liver diseases or conditions
EA201591051A1 (ru) 2013-02-08 2016-06-30 Селджен Авиломикс Рисерч, Инк. Ингибиторы erk и варианты их применения
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
CA3002551A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders
CA3060316A1 (en) 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4659363A (en) * 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
DE3581570D1 (de) * 1984-06-25 1991-03-07 Ciba Geigy Ag Pyrimidinderivate wirksam als schaedlingsbekaempfungsmittel.
ATE112767T1 (de) 1988-03-31 1994-10-15 Mitsubishi Chem Ind Acyclische 6-substituierte pyrimidin nukleosid- abkömmlinge und antivirale mittel, die dieselben als aktive mittel enthalten.
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
JP2895680B2 (ja) * 1992-07-08 1999-05-24 シャープ株式会社 磁気ヘッドおよびその製造方法
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
HUP9900730A3 (en) 1995-11-23 2001-04-28 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE29704863U1 (de) * 1997-03-17 1997-05-22 Gesellschaft für Innenhochdruckverfahren mbH & Co. KG, 73441 Bopfingen Achsschwinge
KR20010041015A (ko) 1998-02-17 2001-05-15 윌리엄 제이. 리플린 항바이러스성 피리미딘 유도체
EP0945442A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
KR100643419B1 (ko) * 1998-03-27 2006-11-10 얀센 파마슈티카 엔.브이. Hiv를 억제하는 피리미딘 유도체
ES2193660T3 (es) * 1998-03-27 2003-11-01 Janssen Pharmaceutica Nv Derivados de pirimidina inhibidores de vih.
HRP20080359B1 (hr) * 1998-11-10 2016-01-01 Janssen Pharmaceutica N.V. PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a
WO2001085699A2 (en) * 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Prodrugs of hiv replication inhibiting pyrimidines

Also Published As

Publication number Publication date
US8003789B2 (en) 2011-08-23
ATE455107T1 (de) 2010-01-15
BG65103B1 (bg) 2007-02-28
TR200101306T2 (tr) 2001-10-22
US20110263625A1 (en) 2011-10-27
SK287269B6 (sk) 2010-05-07
ZA200103769B (en) 2002-08-12
HRP20080359A2 (en) 2008-12-31
CN1214013C (zh) 2005-08-10
WO2000027825A1 (en) 2000-05-18
AU762523B2 (en) 2003-06-26
US20050288278A1 (en) 2005-12-29
EP1270560A1 (en) 2003-01-02
AU6200899A (en) 2000-05-29
LU91528I9 (enExample) 2019-01-02
JP2002529456A (ja) 2002-09-10
LTPA2008016I1 (lt) 2021-04-26
KR100658489B1 (ko) 2006-12-18
HUP0104177A2 (hu) 2002-03-28
AP1683A (en) 2006-11-29
NO2009003I2 (no) 2010-06-07
PT1002795E (pt) 2003-07-31
LTC1002795I2 (lt) 2021-06-10
CY2008021I2 (el) 2010-07-28
OA11674A (en) 2005-01-12
BG105418A (en) 2001-11-30
NL300373I2 (nl) 2009-04-01
NO2009003I1 (no) 2009-03-09
HK1048817B (en) 2010-04-09
HU230394B1 (hu) 2016-04-28
NL300373I1 (nl) 2009-03-02
IL143023A0 (en) 2002-04-21
DE69905683D1 (de) 2003-04-10
DK1002795T3 (da) 2003-06-30
ID28376A (id) 2001-05-17
US20080176880A1 (en) 2008-07-24
US7037917B2 (en) 2006-05-02
ES2193664T3 (es) 2003-11-01
US8530655B2 (en) 2013-09-10
HRP20080359B1 (hr) 2016-01-01
MY121108A (en) 2005-12-30
CA2350801A1 (en) 2000-05-18
EP1002795A1 (en) 2000-05-24
CZ20011533A3 (cs) 2001-10-17
CA2350801C (en) 2008-05-20
SK6032001A3 (en) 2002-01-07
LU91528I2 (fr) 2009-04-20
PL347586A1 (en) 2002-04-08
PL204427B1 (pl) 2010-01-29
DE69941934D1 (de) 2010-03-04
ES2338760T3 (es) 2010-05-12
UA70966C2 (uk) 2004-11-15
NO2021015I1 (no) 2021-03-29
EA004049B1 (ru) 2003-12-25
BR9915552B1 (pt) 2013-11-19
AR024227A1 (es) 2002-09-25
EP1002795B1 (en) 2003-03-05
JP3635238B2 (ja) 2005-04-06
EE200100252A (et) 2002-10-15
NO318801B1 (no) 2005-05-09
DE69905683T2 (de) 2004-03-18
SK287270B6 (sk) 2010-05-07
HK1048817A1 (en) 2003-04-17
FR09C0004I1 (enExample) 2009-02-27
CN1322198A (zh) 2001-11-14
NO20011696L (no) 2001-04-04
NO20011696D0 (no) 2001-04-04
US6878717B2 (en) 2005-04-12
IL169949A (en) 2011-02-28
HRP20010161A2 (en) 2002-02-28
EP1270560B1 (en) 2010-01-13
FR09C0004I2 (fr) 2010-06-11
US20040039005A1 (en) 2004-02-26
HRP20010161B1 (en) 2009-03-31
BR9915552A (pt) 2001-08-14
HUP0104177A3 (en) 2003-01-28
EE05086B1 (et) 2008-10-15
CZ301367B6 (cs) 2010-02-03
ATE233740T1 (de) 2003-03-15
US20030114472A1 (en) 2003-06-19
TWI238161B (en) 2005-08-21
KR20010075235A (ko) 2001-08-09
NZ511116A (en) 2003-08-29
HK1025330A1 (en) 2000-11-10
AU762523C (en) 2004-02-12
DE122009000003I1 (de) 2009-05-20
EA200100536A1 (ru) 2002-02-28
HU227453B1 (en) 2011-06-28
HRP20010161B9 (hr) 2014-10-24
CY2008021I1 (el) 2010-07-28
SI1002795T1 (en) 2003-10-31
AU2011200708A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
BRPI9915552B8 (pt) pirimidinas inibidoras da reprodução do hiv
AP1610A (en) HIV replication inhibiting pyrimidines.
MXPA05008364A (es) Derivados de pirimidina para la prevencion de una infeccion por vih.
AP1468A (en) Hiv inhibiting pyrimidine derivatives.
AP1475A (en) Trisubstituted 1, 3, 5-triazine derivatives for treatment of HIV infections.
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
EE05065B1 (et) Karbamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
BG106526A (en) Therapeutic quinazoline derivatives
NZ526085A (en) Substituted imidazopyridines
MY138308A (en) Hiv replication inhibiting pyrimidines and triazines
JPH11193282A5 (enExample)
ATE233754T1 (de) Diphenyl-piperidin derivate
ATE300178T1 (de) Herbizide wirkstoffkombinationen
TW200626561A (en) HIV inhibiting 5-substituted pyrimidines
YU39503A (sh) Derivati pirimidina
BR9915176A (pt) Derivados de triazina dissubstituìdos nas posições 2,4
ES2196332T3 (es) Derivados de hexahidro-pirido(4,3-b)indol como farmacos antipsicoticos.
ATE500231T1 (de) Hiv hemmende pyrimidin derivate
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
CY1125571T1 (el) Πυριμιδινες που αναστελλουν τον πολλαπλασιασμο toy hiv
UA81654C2 (ru) Пиримидины и триазины, которые ингибируют репликацию вич

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/09/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 24/09/2019